Front. Cell. Infect. Microbiol.

Sec. Clinical Infectious Diseases

Volume 14 - 2024 | doi: 10.3389/fcimb.2024.1497082

Provisionally accepted

The final, formatted version of the article will be published soon.

You have multiple emails registered with Frontiers:

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Background: Lateral flow assay (LFA) has demonstratedshowed high sensitivity and specificity for diagnosing cryptococcosis. However, its role in predictivepredicting value for the therapeutic efficacy offor pulmonary cryptococcosis (PC) remainswas rarely reportedunderexplored.We conducted a retrospective analysis ofon HIV-negative patientsPC with PC to presentdescribe the clinical profile and identify the potential predictors offor radiological prognosis.Results: All the 168 participants received antifungal therapy with a triazole agent. Of these, 84.5% experienced partial or complete absorption of pulmonary lesions. The results of the gamma test, chisquare trend test, and ordinal logistic regression all indicated that both baseline LFA and changes in LFA after treatment were significant both predictors of imaging prognosis. The degree of radiological improvement showed was inverselya downward trend associated with as the baseline LFA positive grade increased (P for linear-by-linear association: 0.011, Spearman correlation coefficient = -0.17; γ= -0.368, P = 0.045). Patients who experiencedwith a decrease in LFA after therapy had a significantly better radiological outcomesprognosis compared to than those with equal or increased LFA (linear-by-linear association, P = 0.014, Spearman correlation coefficient = 0.188; γ = 0.371, P = 0.012).Moreover,Additionally, favorable outcomes were more likely in casespatients with lesions restrictedconfined toin the right lung.Conclusions: LFA has shows the potential toof monitoring radiological outcomes in of PCpulmonary cryptococcosis.

Keywords: Pulmonary cryptococcosis, Lateral flow assay, therapeutic efficacy, radiological prognosis, Lesion distribution, HIV-negative

Received: 16 Sep 2024; Accepted: 18 Dec 2024.

Copyright: © 2024 . This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.